{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"91","value":"33"},{"groupId":"OG002","lowerLimit":"1","upperLimit":"91","value":"33"},{"groupId":"OG003","lowerLimit":"9","upperLimit":"99","value":"67"},{"groupId":"OG004","lowerLimit":"1","upperLimit":"91","value":"33"},{"groupId":"OG005","lowerLimit":"29","upperLimit":"100","value":"100"},{"groupId":"OG006","lowerLimit":"9","upperLimit":"99","value":"67"},{"groupId":"OG007","lowerLimit":"12","upperLimit":"88","value":"50"},{"groupId":"OG008","lowerLimit":"21","upperLimit":"73","value":"47"},{"groupId":"OG009","lowerLimit":"46","upperLimit":"73","value":"60"},{"groupId":"OG010","lowerLimit":"35","upperLimit":"87","value":"64"},{"groupId":"OG011","lowerLimit":"16","upperLimit":"68","value":"40"},{"groupId":"OG012","lowerLimit":"32","upperLimit":"84","value":"60"},{"groupId":"OG013","lowerLimit":"55","upperLimit":"86","value":"72"},{"groupId":"OG014","lowerLimit":"36","upperLimit":"83","value":"61"}]}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"91","value":"33"},{"groupId":"OG002","lowerLimit":"1","upperLimit":"91","value":"33"},{"groupId":"OG003","lowerLimit":"9","upperLimit":"99","value":"67"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG005","lowerLimit":"9","upperLimit":"99","value":"67"},{"groupId":"OG006","lowerLimit":"1","upperLimit":"91","value":"33"},{"groupId":"OG007","lowerLimit":"0","upperLimit":"46","value":"0"},{"groupId":"OG008","lowerLimit":"12","upperLimit":"62","value":"33"},{"groupId":"OG009","lowerLimit":"34","upperLimit":"61","value":"47"},{"groupId":"OG010","lowerLimit":"18","upperLimit":"71","value":"43"},{"groupId":"OG011","lowerLimit":"4","upperLimit":"48","value":"20"},{"groupId":"OG012","lowerLimit":"2","upperLimit":"40","value":"13"},{"groupId":"OG013","lowerLimit":"26","upperLimit":"59","value":"42"},{"groupId":"OG014","lowerLimit":"10","upperLimit":"53","value":"28"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"91","value":"33"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG003","lowerLimit":"1","upperLimit":"91","value":"33"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG005","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG006","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG007","lowerLimit":"0","upperLimit":"46","value":"0"},{"groupId":"OG008","lowerLimit":"4","upperLimit":"48","value":"20"},{"groupId":"OG009","lowerLimit":"9","upperLimit":"31","value":"18"},{"groupId":"OG010","lowerLimit":"5","upperLimit":"51","value":"21"},{"groupId":"OG011","lowerLimit":"0","upperLimit":"32","value":"7"},{"groupId":"OG012","lowerLimit":"2","upperLimit":"40","value":"13"},{"groupId":"OG013","lowerLimit":"5","upperLimit":"29","value":"14"},{"groupId":"OG014","lowerLimit":"0","upperLimit":"27","value":"6"}]}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"91","value":"33"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG003","lowerLimit":"1","upperLimit":"91","value":"33"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG005","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG006","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG007","lowerLimit":"0","upperLimit":"46","value":"0"},{"groupId":"OG008","lowerLimit":"0","upperLimit":"32","value":"7"},{"groupId":"OG009","lowerLimit":"4","upperLimit":"22","value":"11"},{"groupId":"OG010","lowerLimit":"0","upperLimit":"23","value":"0"},{"groupId":"OG011","lowerLimit":"0","upperLimit":"22","value":"0"},{"groupId":"OG012","lowerLimit":"0","upperLimit":"32","value":"7"},{"groupId":"OG013","lowerLimit":"0","upperLimit":"15","value":"3"},{"groupId":"OG014","lowerLimit":"0","upperLimit":"27","value":"6"}]}],"title":"Week 36"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"55"},{"groupId":"OG010","value":"14"},{"groupId":"OG011","value":"15"},{"groupId":"OG012","value":"15"},{"groupId":"OG013","value":"36"},{"groupId":"OG014","value":"18"}],"units":"Participants"}],"description":"Disease control rate was defined as the percentage of participants with CR, PR or stable disease (SD) as per investigator assessment per RECIST version 1.1 after 6, 12, 24 and 36 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.","id":"OG000","title":"Dose Escalation Part: 0.3 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.","id":"OG001","title":"Dose Escalation Part: 0.6 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.","id":"OG002","title":"Dose Escalation Part: 0.9 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.","id":"OG003","title":"Dose Escalation Part: 1.2 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.","id":"OG004","title":"Dose Escalation Part: 1.5 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.","id":"OG005","title":"Dose Escalation Part: 1.8 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG006","title":"Dose Escalation Part: 2.0 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.","id":"OG007","title":"Dose Escalation Part: 2.2 mg/kg"},{"description":"Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG008","title":"Dose Expansion Part: Bladder Cancer"},{"description":"Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG009","title":"Dose Expansion Part: Cervical Cancer"},{"description":"Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG010","title":"Dose Expansion Part: Endometrial Cancer"},{"description":"Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG011","title":"Dose Expansion Part: Esophageal Cancer"},{"description":"Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG012","title":"Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)"},{"description":"Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG013","title":"Dose Expansion Part: Ovarian Cancer"},{"description":"Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG014","title":"Dose Expansion Part: Prostate Cancer"}],"paramType":"NUMBER","populationDescription":"Full analysis set: all participants who had been exposed to tisotumab vedotin in either the dose escalation or expansion parts.","reportingStatus":"POSTED","timeFrame":"At 6, 12, 24 and 36 weeks","title":"Dose Escalation and Expansion Part: Disease Control Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}